Palatin Technologies (PTNT) is a pre-revenue-stage biopharmaceutical with an asset base dominated by cash and a liability stack that is manageable but structurally subordinated by preferred stock liquidation preferences. As of December 31, 2025, total assets were $17.9M against total liabilities of $6.5M, producing reported book equity of $11.5M. Under liquidation-lens haircuts, the recovery picture is modestly positive but thin: cash and equivalents of $14.5M recover at par; accounts receivable of $1.6M recovers at 90-95% (~$1.5M); the $2.0M receivable tagged as ReceivablesNetCurrent (likely the Boehringer Ingelheim milestone receivable) recovers at 90-95% (~$1.9M); prepaid expenses of $1.4M are largely consumed (near-zero recovery); PP&E of $0.11M recovers at roughly 50-70% (~$0.06M to $0.08M); the right-of-use asset of $0.35M recovers at effectively zero on liquidation. Intangibles are nil as tagged. Gross liquidation asset value approximates $18.0M pre-haircut, reducing to roughly $17.8M to $17.9M after haircuts. Against this, face-value liabilities of $6.5M include $5.5M accounts payable, $0.66M accrued liabilities, $0.22M current lease liability, $0.13M noncurrent lease liability, and a materially important $3.8M deferred obligation to Altanispac (disclosed in MD&A and Note 13 as current liabilities as of December 31, 2025, representing a sublicense consideration in the form of non-cash debt cancellation recognized as license revenue in Q3 FY2026). This $3.8M is embedded in AccountsPayableCurrent or a related current liability bucket per the filing—the filing does not separately XBRL-tag it, but MD&A explicitly states it is in current liabilities. Additionally, Series A preferred stock carries a $403K liquidation preference, and Series D preferred stock (issued June 2025, $340K gross proceeds) has a liquidation preference at stated value plus accrued dividends at 8% per annum. Both preferred series rank senior to common equity on liquidation. Net liquidation recovery to common equity, after clearing all face-value liabilities (~$6.5M) and preferred liquidation preferences (~$0.4M to $0.75M depending on accrued dividends), is approximately $10.5M to $11.0M against a share count of approximately 1.76M common shares plus potential preferred conversion shares. The balance-sheet recovery posture improved materially quarter-over-quarter: at September 30, 2025 (prior filing), cash was only $1.3M with current liabilities of $8.2M and a going-concern shadow; the November 2025 offering raised approximately $16.9M net, shifting the recovery from deeply negative to modestly positive. The $3.8M Altanispac deferred liability sitting in current liabilities as of December 31, 2025 is a notable asymmetry—it will extinguish as revenue recognized in Q3 FY2026, effectively converting a current liability to income, but on a December 31 liquidation snap, it faces full face-value claim. Filing discusses the Boehringer Ingelheim remaining performance obligation of EUR 300,000 / USD 346,341 in XBRL, but the larger BI milestone structure and total deal value are discussed in MD&A narrative without separate XBRL tagging for those components.
▼ Community Notes